Subject: Rivaroxaban – Evaluating NoVel and Effective AnticoaguLant Action (REVEAL Survey)
Venous thromboembolism (VTE) is a phenomenon where there is a development of thrombus in a vein. Analysis of clinical studies on post-operative VTE from several Asian countries showed that the incidence of DVT following a general surgery was 13 per cent, 16 per cent following a total hip replacement, 50 per cent in the aftermath of a total knee replacement procedure and 18 per cent following a hip fracture surgery.
Rivaroxaban is used to treat and manage venous thromboembolism as a postoperative thromboprophylaxis for patients undergoing orthopedic surgery to prevent stroke in patients with non-valvular atrial fibrillation and recently has received approval as an add- on drug for secondary prevention of acute coronary syndrome and peripheral arterial disease.
This multicenter survey is planned to understand current perceptions about Rivaroxaban usage, in venous thromboembolism for patients undergoing orthopedic surgery also help to understand the current need gaps at patient level.
We invite you to participate in this survey. On acceptance, you will need to fill the survey questionnaire form provided.
We would encourage you to carefully fill all available information to the fullest in the questionnaire.
If you agree to participate in the said survey, we would request you to sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}
}})